HC Wainwright Issues Optimistic Outlook for DAWN Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Research analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for shares of Day One Biopharmaceuticals in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.28) per share for the quarter, up from their previous estimate of ($0.34). HC Wainwright currently has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals' Q2 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at $0.34 EPS, FY2027 earnings at $0.58 EPS, FY2028 earnings at $1.21 EPS and FY2029 earnings at $1.73 EPS.

A number of other research analysts also recently issued reports on DAWN. Wedbush reaffirmed an "outperform" rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. The Goldman Sachs Group lowered their price objective on Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating for the company in a research report on Monday, February 10th. Bank of America dropped their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Finally, TD Cowen upgraded Day One Biopharmaceuticals to a "strong-buy" rating in a research note on Monday, November 4th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $34.86.

Remove Ads

Day One Biopharmaceuticals Stock Performance

DAWN traded up $0.35 on Friday, hitting $8.60. The company had a trading volume of 2,535,279 shares, compared to its average volume of 1,151,898. The stock has a market capitalization of $871.65 million, a price-to-earnings ratio of -8.35 and a beta of -1.46. The stock has a fifty day moving average price of $12.07 and a 200-day moving average price of $13.33. Day One Biopharmaceuticals has a 12-month low of $8.02 and a 12-month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The business had revenue of $29.21 million during the quarter, compared to analyst estimates of $27.11 million.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. The trade was a 10.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,064 shares of company stock valued at $651,225 over the last quarter. 8.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC raised its position in Day One Biopharmaceuticals by 73.9% during the fourth quarter. FMR LLC now owns 12,887,467 shares of the company's stock valued at $163,284,000 after acquiring an additional 5,475,087 shares in the last quarter. Braidwell LP grew its stake in shares of Day One Biopharmaceuticals by 60.5% during the 3rd quarter. Braidwell LP now owns 4,873,853 shares of the company's stock worth $67,893,000 after purchasing an additional 1,837,949 shares during the period. Franklin Resources Inc. increased its holdings in shares of Day One Biopharmaceuticals by 0.3% during the 4th quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company's stock valued at $49,197,000 after purchasing an additional 13,320 shares in the last quarter. Estuary Capital Management LP lifted its stake in shares of Day One Biopharmaceuticals by 35.5% in the 4th quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company's stock valued at $47,092,000 after purchasing an additional 972,997 shares during the period. Finally, Pictet Asset Management Holding SA boosted its holdings in Day One Biopharmaceuticals by 17.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company's stock worth $44,219,000 after buying an additional 507,398 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.